OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Therapy-Methods & Clinical Development is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Thank you to our 2024 reviewers	152
Exploring human plasma proteomic variations in mucolipidosis type IV	108
Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates	103
Molecular earplugs to protect the inner ear	94
A blood-brain barrier-penetrant AAV gene therapy improves neurological function in symptomatic mucolipidosis IV mice	93
Genetic surgery for a cystic fibrosis-causing splicing mutation	91
Genome Editing in Patient iPSCs Corrects the Most Prevalent USH2A Mutations and Reveals Intriguing Mutant mRNA Expression Profiles	84
Micro-dystrophin gene therapy demonstrates long-term cardiac efficacy in a severe Duchenne muscular dystrophy model	77
Preclinical evaluation of NG101, a potential AAV gene therapy for wet age-related macular degeneration	70
First use of adeno-associated viruses in the human inner ear	66
CRISPR-Cas9 correction of a nonsense mutation in LCA5 rescues lebercilin expression and localization in human retinal organoids	58
Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy	49
Biodistribution of AAV1, AAV5, AAV9, and AAVDJ serotypes after intra-cisterna magna delivery in non-human primates	48
Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution	47
Innate and adaptive AAV-mediated immune responses in a mouse model of Duchenne muscular dystrophy	47
Protein phosphatase 2A anchoring disruptor gene therapy for familial dilated cardiomyopathy	46
Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication	46
Unfolding of viral protein 1 N-termini facilitates genome ejection from recombinant adeno-associated virus serotype 8	45
Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering	44
Circulating neurofilaments to track dorsal root ganglion toxicity risks with AAV-mediated gene therapy	44
Identification of the role of SNARE proteins in rAAV vector production through interaction with the viral MAAP	44
Molecular Therapy Advances: Building the bridge between discovery and cure	40
A sensitive AAV transduction inhibition assay assists evaluation of critical factors for detection and concordance of pre-existing antibodies	39
The unknown impact of conditioning on HSC engraftment and clonal dynamics	39
Efficacy and muscle safety assessment of fukutin-related protein gene therapy	37

Dose-finding and in vivo safety study of an adipose targeted leptin gene therapy for congenital leptin deficiency	37
Modulation of AAV transduction and integration targeting by topoisomerase poisons	37
Deconvolution of spatial sequencing provides accurate characterization of hESC-derived DA transplants in vivo	36
Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia	35
An HPLC-SEC-based rapid quantification method for vesicular stomatitis virus particles to facilitate process development	34
Quantification of full and empty particles of adeno-associated virus vectors via a novel dual fluorescence-linked immunosorbent assay	34
An investigation of the immune epitopes of adeno-associated virus capsid-derived peptides among hemophilia patients	33
Synergy between Lactobacillus murinus and anti-PcrV antibody delivered in the airways to boost protection against Pseudomonas aeruginosa	33